New Triple-Threat attack on aggressive blood cancer
NCT ID NCT07311746
Summary
This study is testing whether combining three existing drugs—ruxolitinib, cladribine, and venetoclax—can help control a rare and aggressive form of T-cell leukemia that has returned or not responded to prior treatment. The main goals are to see if the combination is safe and if it can shrink the cancer. The trial will enroll about 36 adults who have this specific type of leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL PROLYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.